AXPAXLI™ (also known as OTX-TKI), an investigational axitinib hydrogel administered by intravitreal injection, combines a highly potent and selective tyrosine kinase inhibitor (TKI) with our proven proprietary hydrogel. Phase 1 data provided a compelling foundation to advance toward Phase 3, with the goal to dramatically improve durability and long-term outcomes for patients with wet AMD, and the potential to impact other retinal disease.8-12
Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including the ones under development on this website.
All investigational product candidates are currently undergoing clinical evaluation. This content is not intended to convey any conclusion of safety or efficacy, and there is no guarantee that any product candidate will successfully complete development or gain FDA approval or other regulatory authority approval.
Redefining development
Complementary wet AMD registrational trials designed to show durability, repeatability, and flexibility of AXPAXLI
1. Wang W, et al. Int J Mol Sci. 2018;19(6):1816. 2. Di Carlo E, et al. J Clin Med. 2021;10(15):3297. 3. Market Scope. 2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases. St. Louis, MO: Market Scope, LLC. 2024. 4. Data on file 01892. Anti-VEGF Revenue. Ocular Therapeutix, Inc. 5. Market Scope. Ophthalmic Market Trends: Quarterly US Retina Edition. St. Louis, MO: Market Scope, LLC. 2025. 6. Khanani AM, et al. Ophthalmology Retina. 2020;4(2):122-133. 7. Evans RN, et al. JAMA Ophthalmol. 2020;138(10):1109. 8. Zhao Y, et al. Oncologist. 2015;20(6):660-673. 9. Gross-Goupil M, et al. Clin Med Insights Oncol. 2013;7:269-277. 10. Liang C, et al. Mol Ther Oncolytics. 2022;24:577-584. 11. Blizzard CD, Inventors, Ocular Therapeutix, Inc., Assignee. Ocular implant containing a tyrosine kinase inhibitor. US Patent 11,439,592 B2. September 13, 2022. 12. Tyson SL, et al. J Cataract Refract Surg. 2019;45(2):204-212. 13. Sawhney AS, et al., Inventors, Incept, LLC, Assignee. Drug delivery through hydrogel plugs. US Patent 8,409,606 B2. April 2, 2013. 14. Blizzard C, et al. Clin Ophthalmol. 2021:15 2055–2061. 15. Boyer DS, et al. Evaluating Safety, Tolerability and Biological Activity of OTX-TKI, a Hydrogel-Based, Sustained-Release Intravitreal Axitinib Implant, in Subjects with Neovascular Age-Related Macular Degeneration. Presented at: American Academy of Ophthalmology Annual Meeting; November 13-15, 2020; Virtual. 16. Goldstein MH, et al. Invest Ophthalmol Vis Sci. 2020;61(7):4266. 17. McGrath M, et al. Invest Ophthalmol Vis Sci. 2014;55:472. 18. Data on file DOF 030. Ocular Therapeutix, Inc.
AXITINIB targets
AXITINIB is a highly potent and selective small molecule pan-VEGFR inhibitor 9-11
ELUTYXTM delivers
ELUTYX is a fully bioresorbable, clinically established hydrogel platform that is designed for sustained and targeted drug delivery, aiming to maximize efficacy to provide optimal disease control12-17